Dr. Ana Maria Cuebas, MD

Dr. Cuebas practices at McIntosh Trail Community Service Board in Griffin, Georgia.

Dr. Cuebas' NPI, 1417277997, was assigned on June 7, 2010. Dr. Cuebas holds Georgia license 72866.

Dr. Cuebas' primary practice is McIntosh Trail Community Service Board, at 1435 N Expy, Griffin, GA 30223 in Spalding County. The practice phone is (770) 358-5252.

Dr. Cuebas' primary practice is McIntosh Trail Community Service Board in Griffin, Georgia. The medical group on file is McIntosh Trail Community Service Board. Dmand AI also links Dr. Cuebas to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cuebas practices. Vendor and product names are available with a free account.

Psychiatry is Dr. Cuebas' primary specialty in the NPI Registry, under taxonomy code 2084P0800X. Dr. Cuebas is licensed in Georgia.

CMS data shows 42 Medicare services from Dr. Cuebas across 1 procedure code in 2024, all of them office visits, for 14 Medicare patients. Medicare paid $2,637 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 14 Medicare patients who saw Dr. Cuebas in 2024. The largest group is 75 to 84, with 0 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.84, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cuebas' median patient age at 48, with 53% women.

In 2024, Dr. Cuebas wrote 1,377 Medicare Part D claims for 61 patients. 88% of them were for generic drugs. CMS names the drug for 1,298 of them, across 41 drugs with 11 or more claims each, at $407,432 in total drug cost. In 2023, CMS named 1,306 claims across 39 drugs.

Dr. Cuebas accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cuebas as offering telehealth.

CMS Open Payments shows 551 general payments to Dr. Cuebas from 20 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. Otsuka America Pharmaceutical, Inc. paid the most, $1,763.